Patient-Reported Symptom Severity, Health-Related Quality of Life, and Emotional Distress Trajectories During and After Radiation Therapy for Human Papillomavirus–Associated Oropharyngeal Cancer: A TROG 12.01 Secondary Analysis

- McDowell, Lachlan, Bressel, Mathias, King, Madeleine T., Corry, June, Kenny, Lizbeth, Porceddu, Sandro, Wratten, Christopher, Macann, Andrew, Jackson, James E., Rischin, Danny

Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial

- Joseph, David, Denham, James W., Turner, Sandra, Kenny, Lizbeth, Christie, David, Tai, Keen-Hun, Gogna, NirdoshK, Kearvell, Rachel, Murray, Judy, Ebert, Martin A., Haworth, Annette, Delahunt, Brett, Steigler, Allison, Oldmeadow, Christopher, Attia, John, Lamb, David S., Spry, Nigel A., Stanley, John, Shannon, Tom, Duchesne, Gillian, Atkinson, Chris, Matthews, John H. L.

Validation of local p16 testing for determination of human papilloma virus status eligibility on a low risk oropharyngeal cancer trial - A Trans-Tasman Radiation Oncology Group study

- Young, Richard J., Solomon, Benjamin, Rischin, Danny, Corry, June, Angel, Christopher, Kenny, Lizbeth, Porceddu, Sandro, Wratten, Christopher, Macann, Andrew, Jackson, James E., Herschtal, Alan

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial

- Denham, James W., Joseph, David, Lamb, David S., Spry, Nigel A., Duchesne, Gillian, Matthews, John, Atkinson, Chris, Tai, Keen-Hun, Christie, David, Kenny, Lizbeth, Turner, Sandra, Gogna, Nirdosh Kumar, Diamond, Terry, Delahunt, Brett, Oldmeadow, Chris, Attia, John, Steigler, Allison

Effect of p16 status on the quality-of-life experience during chemoradiation for locally advanced oropharyngeal cancer: a substudy of randomized trial Trans-Tasman Radiation Oncology Group (TROG) 02.02 (HeadSTART)

- Ringash, Jolie, Fisher, Richard, Peters, Lester, Trotti, Andy, O'Sullivan, Brian, Corry, June, Kenny, Lizbeth, Van Den Bogaert, Walter, Wratten, Chris, Rischin, Danny

Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial

- Denham, James W., Steigler, Allison, Tai, Keen-Hun, Gogna, Nirdosh Kumar, Gill, Suki, Tan, Hendrick, Kearvell, Rachel, Murray, Judy, Ebert, Martin, Haworth, Annette, Kennedy, Angel, Delahunt, Brett, Joseph, David, Oldmeadow, Christopher, Holliday, Elizabeth G., Attia, John, Lamb, David S., Spry, Nigel A., Duchesne, Gillian, Atkinson, Chris, Matthews, John, Turner, Sandra, Kenny, Lizbeth

Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial

- Denham, James W., Wilcox, Chantelle, Gogna, Nirdosh Kumar, Kenny, Lizbeth, Duchesne, Gillian, Delahunt, Brett, McElduff, Patrick, Joseph, David, Spry, Nigel A., Lamb, David S., Tai, Keen-Hun, Matthews, John, Atkinson, Chris, Turner, Sandra, Christie, David

A randomised trial investigating the effect on biochemical (PSA) control and survival of different durations of adjuvant androgen deprivation in association with definitive radiation treatment for localised carcinoma of the prostate

- Lamb, David, Joesph, David, Turner, Sandra, Diamond, Terry, Steigler, Allison, Attia, John, Delahunt, Brett, Haworth, Annette, Denham, Jim, Duchesne, Gillian, Atkinson, Chris, Kenny, Lizbeth, Gogna, Kumar, Matthews, John, Spry, Nigel, Tai, Keen-Hun